Virus therapy joins Chemo-Radiation in fight against rectal cancer
NCT ID NCT06459869
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment called NG-350A, a virus designed to stimulate the immune system inside tumors, combined with standard chemoradiotherapy for people with locally advanced rectal cancer. The study aims to see if this combination can improve the chance of the tumor disappearing completely before surgery. About 30 adults with a specific type of rectal cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NG-350A (a virus that delivers an immune-stimulating protein to tumors), capecitabine (chemotherapy), and radiotherapy
What this could lead to
If it works, this could point toward a more effective treatment for locally advanced rectal cancer, potentially increasing the chance of a complete response before surgery.
What could go wrong
This is an early phase 1 trial with only 30 participants, so results may not apply broadly. The combination may cause significant side effects, and the virus-based therapy might not work as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
AdventHealth Orlando
RECRUITINGOrlando, Florida, 32804, United States
Contact
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
-
The Royal Marsden NHS Foundation Trust
RECRUITINGSutton, United Kingdom
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University College London NHS FT
RECRUITINGLondon, United Kingdom
Contact
-
University of Southern California
ACTIVE_NOT_RECRUITINGLos Angeles, California, 90033, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact